Frederick H Hausheer

This inventor holds 83 USPTO granted patents and 2 published patent applications, plus 10 CIPO patents and 16 EPO patents, primarily in Cancer Treatment (CPC class 514283). Top assignees: Bionumerik Pharmaceuticals, Inc., Sterling Drug Inc., Lantern Pharma Inc.. Active years: 1993-2022.

USPTO Granted Patents = 83 (Patent Applications = 2)

% Patents Active = 84.3

CIPO Patents = 10 (Patent Applications = 9)

EPO Patents = 16 (Patent Applications = 8)

Average Co-Inventor Count = 1.9

ph-index = 13

Forward Citations = 1,867(Granted Patents)

Forward Citations (Not Self Cited) = 1,733(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boerne, TX (US) (1999 - 2016)
Fair Oaks Ranch, TX (US) (2007 - 2019)
San Antonio, TX (US) (1993 - 2022)

Company Filing History:

74 out of 91

Bionumerik Pharmaceuticals, Inc.

Sterling Winthrop Inc.

patents

6. 4 out of 834,411

Other

patents

Years Active: 1993-2022

Loading Chart...

Areas of Expertise:

Cancer Patient Survival

Chemoprotective Methods

Dithio Compounds

Camptothecin Analogs

Taxane-Induced Neurotoxicity

Platinum Complexes

Drug Formulations

Toxicity Reduction

Chemotherapy Resistance

Ovarian Cancer Treatment

Anticancer Compounds

Enantiomerically-Pure Synthesis

83 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11471431 - Increasing cancer patient survival time by administration of dithio-containing compounds (2022-10-18),

2. 10413538 - Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer (2019-09-17),

3. 9320760 - Compositions and methods of use of compounds to increase cancer patient survival time (2016-04-26),

4. 9023805 - Increasing cancer patient survival time by administration of dithio-containing compounds (2015-05-05),

5. 8722886 - Methods for the total chemical synthesis of enantiomerically-pure 7-(2'-trimethylsilyl)ethyl camptothecin (2014-05-13),

6. 8710095 - Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity (2014-04-29),

7. 8569265 - Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4′:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof (2013-10-29),

8. 8143236 - Chemoprotective methods (2012-03-27),

9. 8026227 - Chemoprotective methods and compositions (2011-09-27),

10. 7829541 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents (2010-11-09),

11. 7829540 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents (2010-11-09),

12. 7829539 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents (2010-11-09),

13. 7829538 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents (2010-11-09),

14. 7829117 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents (2010-11-09),

15. 7777060 - Platinum analogs with bis-nitrile-containing ligands (2010-08-17),

Title: Innovator Spotlight: Frederick H Hausheer - Pioneering Cancer Treatment Advancements

Introduction:

Frederick H Hausheer is a distinguished inventor from Boerne, TX (US) with a remarkable portfolio of 83 patents. His groundbreaking work in the field of oncology has significantly impacted cancer treatment methodologies, especially in cases of advanced ovarian cancer. Let's delve into the contributions and achievements of this prolific inventor.

Latest Patents:

Hausheer's recent patents include revolutionary treatments aimed at increasing cancer patient survival time. The administration of dithio-containing compounds, focusing on thioredoxin and glutaredoxin overexpression, has shown promising results in enhancing the effectiveness of chemotherapy interventions. Additionally, his work on Karenitecin for platinum and taxane chemotherapy-resistant ovarian cancer has opened new avenues for improving patient outcomes.

Career Highlights:

With a strong background in pharmaceuticals, Frederick H Hausheer has been a key figure at Bionumerik Pharmaceuticals, Inc. His expertise in developing innovative treatments for challenging medical conditions has been pivotal in shaping the landscape of cancer therapeutics. Hausheer's dedication to research and development has led to the successful implementation of novel pharmaceutical compositions that target specific cancer markers.

Collaborations:

Throughout his career, Hausheer has collaborated with esteemed professionals in the field of oncology. Notable coworkers include Kochat Haridas and Dhanabalan Murali, who have played integral roles in advancing cancer treatment methodologies alongside him. These collaborations have facilitated the exchange of ideas and expertise, leading to significant advancements in cancer research.

Conclusion:

Frederick H Hausheer's remarkable contributions to the field of oncology underscore his commitment to improving patient outcomes and advancing cancer treatment methodologies. His innovative approach to developing novel pharmaceutical compositions has set a new standard in personalized medicine, particularly for patients with advanced ovarian cancer. Hausheer's dedication to research and collaboration serves as an inspiration to aspiring inventors and underscores the profound impact that innovation can have on healthcare practices.